Recently,Madrigal Pharmaceuticals, Inc.AndArrowhead PharmaceuticalsReached an exclusive globalLicense Agreement, According to the agreement,MadrigalObtainsiRNA TherapyARO-PNPLA3TheGlobal exclusive rights for development, production, and commercialization。For this reason,MadrigalWill PayArrowhead$25 millionTheAdvance Payment，Up to $975 millionTheMilestone Payment、And the futureSales Split。This is Madrigal's year inMASH（Metabolic Dysfunction-Associated Steatohepatitis) The second deal reached in the field, with the first product launchedMASH drug and already inIn the case of market leadership，Madrigal is still actively expanding.MASH Pipeline.Products that were once returnedActually,ARO-PNPLA3Authorized toMadrigalPreviously, there wasHistory of Returns.In October 2018, Arrowhead and Johnson & Johnson/Yang Sencheng's Cooperation，The CooperationCoverARO-PNPLA3IncludingFourArticlePipeline, with a total transaction amount reaching 3.7 billion US dollars. But in 2023February,Johnson & Johnson announcedAbandon ARO-PNPLA3TheRights, Arrowhead Regains All Its Rights。
ARO-PNPLA3Is an RNA interference (RNAi) Therapy,Aiming atTreating MASH by silencing the expression of the PNPLA3 gene in hepatocytes. The PNPLA3 gene mutation (I148M) isMASHProgression of Known Genetic FactorsTransmission driving factors,Significantly associated with the risk of hepatic steatosis, inflammation, fibrosis, and hepatocellular carcinoma.Previously, the company published in The New England Journal of MedicineⅠPhase Clinical DataDisplay, viaAfter a single dose (The12 Weeks），Patients with PNPLA3 I148M Homozygous MutationTheLiver fat reduced by up to 46%（Measured by MRI-PDFF）。Good safety profile, no clinically significant adverse events observed。
Currently, Madrigal plans to combine ARO-PNPLA3 with its marketed drug Rezdiffra to exploreFor the "metabolic + genetic" dual intervention in MASH, the company stated that it would communicate with the FDA to design Rezdiffra and ARO-PNPLA3.ⅡCombination Therapy Trial。Continuously Consolidate MASH PositionThanks toRezdiffra's Strong Sales Performance，MadrigalHas now become the currentMarket leader in the MASH field.
AsThe FirstNASH Drugs, Rezdiffra has been approved in China since March 2024FDA Accelerated Approval for Market LaunchSince,Sales growth was very strong, reaching sales in the year of listing$1.801 billion, Full-Year 2025 Net SalesApproaching $1 billion (958.4 millionUSD), the sameCompared to growth432%。CompanyIt is expected that,TodayYearRezdiffraStillWill continue to achieve strong net sales growth。
And at the same time, in order toConsolidation inIn the MASH fieldLeadership Position，Madrigal is stillAccelerate ExpansionMASH's Product Line Layout。
Currently,In Madrigal's pipelineAt leastWith more than 10MASHProject portfolio, the company aims to "Rezdiffra"Cornerstone,By exploring itsCompared with oral GLP-1, DGAT-2 inhibitors,siRNACombination drug strategy to consolidate its futureIn the MASH fieldLong-term leadership position.
In February this year,In order to expand MASH's product line,MadrigalAlso reached a cooperation agreement worth up to $4.4 billion with Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals, introducing six preclinical siRNA projects from the latter.。https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-adds-clinical-stage-sirna-asset-targeting-pnpla3-itshttps://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-expands-its-mash-pipeline-exclusive-global-licensinghttps://ir.madrigalpharma.com/static-files/b5e4ac70-1e1b-4d55-b999-ed7200873384
